ABEJA
Pharmaceuticals, namely, proteins, antibodies, and large molecules for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system related diseases and disorders, and infectious diseases, blood disorders, obesity, and cognitive disorders; none of the foregoing including external use pain reliever pre...
Pending · August 4, 2020 · 90092806 ·